Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IL-1 trap. Regeneron/Novartis.

Cem Gabay1

  • 1Division of Rheumatology, University Hospital of Geneva, 26 Avenue Beau-Séjour, 1211 Geneva 14, Switzerland. cem.gabay@hcuge.ch

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2003
PubMed
Summary

Regeneron and Novartis are developing IL-1 trap, an interleukin-1 antagonist, for rheumatoid arthritis treatment. Phase II trial results are anticipated in mid-2003.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Free IL-18 in NLRC4-associated autoinflammatory disease without macrophage activation syndrome.

Rheumatology (Oxford, England)·2026
Same author

Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases.

Nature reviews. Rheumatology·2026
Same author

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

The Lancet. Rheumatology·2026
Same author

IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma.

Cancer immunology research·2026
Same author

[Rheumatoid arthritis pathogenesis. From susceptibility to autoimmunity, and arthritis].

Revue medicale suisse·2026
Same author

Pyrin inflammasome activation triggers an IL-18-driven IFN-γ response in mevalonate kinase deficiency.

The Journal of allergy and clinical immunology·2026

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
  • Interleukin-1 (IL-1) plays a significant role in the pathogenesis of RA.

Purpose of the Study:

  • To evaluate the efficacy and safety of IL-1 trap, an IL-1 antagonist, in patients with rheumatoid arthritis.

Main Methods:

  • A Phase II clinical trial was initiated in July 2002.
  • The study involves co-development by Regeneron and Novartis.

Main Results:

  • Results from the Phase II trial are expected in mid-2003.
  • Data on efficacy and safety are pending.

Conclusions:

  • The IL-1 trap represents a potential novel therapeutic approach for rheumatoid arthritis.
  • Further clinical evaluation is necessary to confirm its therapeutic value.

Related Experiment Videos